Cell Therapeutics (CTIC) Jumps On News
August 24, 2009 · Filed Under R&D
Cell Therapeutics, Inc. (CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company’s New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL).
Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from currently marketed anthracyclines and other related chemotherapy agents.
The market is still skeptical about the company’s actions. Shares are up only 4% to $1.77, but volume is large at almost 10 million shares
Douglas A. McIntyre
